Continue reading this on our app for a better experience
Open in App
Sign In
Subscribe
premium
latest
news
views
capital
digital edge
options
haven
videos
edgeinvest
events
Subscribe
Home
Capital
Covid-19
PREMIUM
Covid-19
BioNTech beats estimates as vaccine maker pursues more diseases
Bloomberg
Mon, May 08, 2023 • 07:50 PM GMT+08
•
• 2 min read
Last month, BioNTech began an early stage trial for mRNA vaccines against tuberculosis
Follow us on
Facebook
and join our
Telegram
channel for the latest updates.
TAGS
Covid-19
BioNTech
Related News
IPO
Medical supplies firm Pasture Holdings aims to raise $5 million via all-placement IPO
by The Edge Singapore
•
May 31, 2023
Covid-19
Covid-19 global health emergency is over after three years: WHO
by Bloomberg
•
May 07, 2023
Tech
Working from home and the last shoe to drop
by Assif Shameen
•
April 26, 2023
Subscribe
Highlights
Investing strategies
US stock faithful ride US$7 trillion rally as market timing backfires
December 09, 2023
Trending Now
Seatrium secures FPSO topside modules fabrication contract from MODEC
Is it time to add into S-REITs despite the sector's 7% gain in November?
Seatrium appoints Adrian Teng as new CFO
ComfortDelGro raising taxi fare structure with effect from Dec 13
OCBC's Wong reaffirms One Bank vision with eyes firmly on shareholders’ returns
Related News
IPO
Medical supplies firm Pasture Holdings aims to raise $5 million via all-placement IPO
May 31, 2023
Covid-19
Covid-19 global health emergency is over after three years: WHO
May 07, 2023
Tech
Working from home and the last shoe to drop
April 26, 2023
Subscribe
×
Loading next article...
Download The Edge Singapore App
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
Subscribe
Products & Services
News
Newsletter
Videos
Options
Edge Invest
Advertising
T&Cs
Sitemap
About Us
Our Company
Contact Us
Editorial Team
Join Us
FAQs
Privacy Policy
Malaysia
© 2023 The Edge Publishing Pte Ltd. All rights reserved.